And while this is a nice outcome for Merck's Clesrovimab, also known as MK-1654, there are several entrenched on market franchises. So this is not likely to materially helpful, in the near term. Here's Fierce's fine reporting on it all:
. . .Moderna recently became the latest biopharma to score an approval to prevent respiratory syncytial virus (RSV), but Merck & Co. hopes to be the next in line with new data showing a monoclonal antibody reduced the incidence of RSV-related infections in infants. . . .
“We are encouraged by these findings and look forward to working with regulators to provide a new option to help address the impact of RSV on infants and their families,” Paula Annunziato, senior vice president of infectious diseases and vaccines, Global Clinical Development, Merck Research Laboratories, said in the release.
Merck once had an RSV vaccine for adults in early-stage development, but passed it over to long-time partner Moderna in 2020 to focus on what would become clesrovimab. For its part, Moderna has powered ahead in the RSV space, scoring FDA approval for an adult RSV vaccine in May. . . .
For now, the market remains dominated by GSK’s Arexvy shot. . . and yes, this is "legacy" power alley stuff.
Now you know -- onward, smiling.
नमस्ते
No comments:
Post a Comment